![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
A budget optimization analysis for the treatment and potential
elimination of hepatitis C virus infection in the United States
|
|
|
Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
Olivier Ethgen1,2, Yuri Sanchez Gonzalez3, Jordan J. Feld4
1SERFAN innovation, Namur, Belgium; 2University of Liege, Liege, Belgium; 3AbbVie Inc., North Chicago, IL, USA; 4Toronto Centre for Liver Disease, Toronto, ON, Canada
![0503171](../images/050317/050317-10/0503171.gif)
![0503172](../images/050317/050317-10/0503172.gif)
![0503173](../images/050317/050317-10/0503173.gif)
![0503174](../images/050317/050317-10/0503174.gif)
![0503175](../images/050317/050317-10/0503175.gif)
![0503176](../images/050317/050317-10/0503176.gif)
![0503177](../images/050317/050317-10/0503177.gif)
![0503178](../images/050317/050317-10/0503178.gif)
![0503179](../images/050317/050317-10/0503179.gif)
![05031710](../images/050317/050317-10/05031710.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|